AMAM
Ambrx Biopharma, Inc. Common Stock
AMAM
AMAM
Delisted
AMAM was delisted on the 6th of March, 2024.
14 hedge funds and large institutions have $45.4M invested in Ambrx Biopharma, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 6 reducing their positions, and 1 closing their positions.
Holders
14
Holders Change
–
Holders Change %
0%
% of All Funds
0.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
6
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
1
Fidelity Investments
Boston,
Massachusetts
|
$10.2M |
| 2 |
2
UBS Group
Zurich,
Switzerland
|
$1K |
Top Sellers
| 1 |
OCA
1
Octagon Capital Advisors
New York
|
$325K |
| 2 |
2
Renaissance Technologies
New York
|
$29K |
| 3 |
3
Norges Bank
Oslo,
Norway
|
$165K |
| 4 |
4
Morgan Stanley
New York
|
$0 |
| 5 |
5
Millennium Management
New York
|
$272K |
